Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Bersani, Francesca; Morena, Deborah; Picca, Francesca; Morotti, Alessandro; Tabbò, Fabrizio; Bironzo, Paolo; Righi, Luisella; Taulli, Riccardo

Bersani, Francesca; Morena, Deborah; Picca, Francesca; Morotti, Alessandro; Tabbò, Fabrizio; Bironzo, Paolo; Righi, Luisella; Taulli, Riccardo.

Afiliación

Bersani F; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Morena D; Department of Oncology, University of Torino, 10043 Orbassano, Italy.
Picca F; Center for Experimental Research and Medical Studies (CeRMS), AOU Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
Morotti A; Department of Oncology, University of Torino, 10043 Orbassano, Italy.
Tabbò F; Center for Experimental Research and Medical Studies (CeRMS), AOU Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
Bironzo P; Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, Italy.
Righi L; Thoracic Unit and Medical Oncology Division, Department of Oncology at San Luigi Hospital, University of Torino, 10043 Orbassano, Italy.
Taulli R; Department of Oncology, University of Torino, 10043 Orbassano, Italy.

Transl Lung Cancer Res ; 9(6): 2629-2644, 2020 Dec.

Article en En | MEDLINE | ID: mdl-33489823

Palabras clave

Circulating tumor cells (CTCs); EGFR-mutant NSCLC; KRASG12C inhibitors; circulating tumor DNA (ctDNA); drug tolerance; tumor organoids

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google